Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of $107.00. The company’s shares closed la ...

DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience ...

Stock futures dipped on Thursday as investors weighed President Trump’s 90-day tariff reprieve for select countries, which ...

Trump Media and Technology Group (DJT) has tied up with asset manager Yorkville America Equities and Index Technologies Group to launch Truth Social-branded Separately Managed Accounts.

In addition to Citi, Dexcom also received a Buy from Raymond James’s Jayson Bedford in a report issued yesterday. However, today, Barclays maintained a Hold rating on Dexcom (NASDAQ: DXCM). The ...

DexCom (NasdaqGS:DXCM) experienced an 12% decline over the past week, during which the company transitioned its audit from Ernst & Young to Deloitte & Touche, and appointed Jon Coleman as Chief ...

Fintel reports that on April 10, 2025, Mizuho initiated coverage of DexCom (NasdaqGS:DXCM) with a Outperform recommendation. Analyst Price Forecast Suggests 57.82% Upside As of April 1, 2025, the ...

DexCom Inc. closed 51.60% short of its 52-week high of $139.24, which the company achieved on April 25th.

In its fourth quarter 2024 investor letter, Sands Capital Select Growth Fund emphasized stocks such as DexCom, Inc. (NASDAQ:DXCM). DexCom, Inc. (NASDAQ:DXCM) is a medical device company that develops ...

Dexcom advanced the launch of Stelo, its over-the-counter product for non-insulin type 2 diabetes, pre-diabetes, and ...